Following is a summary of current health news briefs. Brazil approves Pfizer vaccine for children as young as six months Brazilian national health regulator Anvisa has approved the COVID-19 vaccine produced by Pfizer and BioNTech for children aged between six months and four years, the government body said in a statement Friday night.
BRASILIA. KAZINFORM - A year and a half after the approval of the emergency use of the CoronaVac vaccine against COVID-19, Brazil’s national drug regulator Anvisa received the application for its definitive registration. The request was sent by the Butantan Institute of São Paulo, Agencia Brasil reports.
BRASILIA. KAZINFORM Brazil’s national drug authority Anvisa on Wednesday (Mar. 30) granted emergency authorization to COVID-19 treatment drug Paxlovid, a combination of nirmatrelvir and ritonavir. The product is manufactured by pharmaceutical company Wyeth.
People entering the country who have not been vaccinated will still need to show proof of a negative COVID-19 test result, but quarantining will be eliminated immediately. Travelers' health declarations used for tracing COVID cases will no longer be required, with immediate effect, while testing for vaccinated travelers will be suspended from May 1, Anvisa said.
ANVISA (Brazilian Health Authority) approved Biophytis' Expanded Access Program (EAP) for hospitalized patients with severe COVID-19 and mechanically ventilated in Intensive Care UnitSarconeos (BIO101)